[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608262":3},{"organization":4,"armGroups":7,"interventions":37,"overallOfficials":42,"centralContacts":50,"locations":56,"responsibleParty":76,"collaborators":42,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":42,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":42,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":59,"whyStopped":42,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","INDUSTRY",[8,15,18,21,24,27,31,34],{"label":9,"type":10,"description":11,"interventionNames":12},"group 1","EXPERIMENTAL","single dose",[13,14],"Biological: GR2303 injection","Biological: Placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"group 2",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"group 3",[13,14],{"label":22,"type":10,"description":11,"interventionNames":23},"group 4",[13,14],{"label":25,"type":10,"description":11,"interventionNames":26},"group 5",[13,14],{"label":28,"type":10,"description":29,"interventionNames":30},"group 6","multiple dose",[13,14],{"label":32,"type":10,"description":29,"interventionNames":33},"group 7",[13,14],{"label":35,"type":10,"description":29,"interventionNames":36},"group 8",[13,14],[38,43,46,48],{"type":39,"name":40,"description":11,"armGroupLabels":41,"otherNames":42},"BIOLOGICAL","GR2303 injection",[9,16,19,22,25],null,{"type":39,"name":44,"description":11,"armGroupLabels":45,"otherNames":42},"Placebo",[9,16,19,22,25],{"type":39,"name":40,"description":29,"armGroupLabels":47,"otherNames":42},[28,32,35],{"type":39,"name":44,"description":29,"armGroupLabels":49,"otherNames":42},[28,32,35],[51],{"name":52,"role":53,"phone":54,"phoneExt":42,"email":55},"Nian","CONTACT","021-50805989-08324","nianhanli@genrixbio.com",[57],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"Beijing Friendship hospital, Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100050","China","CN",{"type":66,"coordinates":67},"Point",[68,69],116.39723,39.9075,{"lat":69,"lon":68},[72],{"name":73,"role":53,"phone":74,"phoneExt":42,"email":75},"Professor Dong","010-63139003","Ruihua_Dong_RW@163.com",{"type":77,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100608262","phase-1-a-study-to-evaluate-the-safety-immunogenicity-and-pharmacokinetics-of-gr2303-in-healthy-adult-100608262",false,"NCT07199270","A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult","A Randomized, Double-blind, Placebo-controlled of GR2303 Injection in Healthy Adult Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacologic of GR2303","Inclusion Criteria:\n\n1. Healthy adult subjects\n2. Signed informed consent\n\nExclusion Criteria:\n\n1. History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects.\n2. Prior use of drug targeting TNF-like cytokine 1A\n3. history of malignant tumor\n4. psitive results for Hepatitis B surface antigen (HBsAg), anti Hepatitis C antibody (HCV Ab) or human immunodeficiency virus (HIV)",true,"ALL","18 Years","45 Years",{"count":90,"type":91},64,"ESTIMATED","INTERVENTIONAL",[94],"PHASE1","he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups",[97],"Health Adult Subjects",[99,100,101],"Inflamatory bowel disease","phase 1","GR2303","2025-09-22",{"date":104,"type":105},"2025-09-30","ACTUAL",{"date":107,"type":105},"2025-09-18",{"date":109,"type":91},"2026-12-16",{"name":5,"class":6},1]